GROWTHFORGE · BEACON · SOURCE-BACKED SIGNAL
CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer
NCT06039202 is on the Cheap-to-Truth Radar because its public ClinicalTrials.gov record contains a recent development signal worth inspecting. This page is not a recommendation or diligence conclusion.
Priority to inspect80/100
StatusSUSPENDED
PhasePHASE2
Lead sponsorHoly Stone Healthcare Co., Ltd
Last update2026-09-18
Public-record facts
| Intervention | CA102N (DRUG), TAS-102 (DRUG), Bevacizumab (BIOLOGICAL) |
|---|---|
| Condition | Metastatic Colorectal Cancer |
| Enrollment | 100 |
| Why stopped | Strategy under discussion |
| Results posted | No / not indicated |
Why Beacon surfaced it
- The record is suspended and was updated 2026-09-18.
- It is an interventional PHASE2 study with a named drug/drug/biological intervention.
- The lead sponsor is classified as industry.
- The record states a reason for stopping, creating a concrete diligence question.
What Cheap-to-Truth would verify next
- Was the stopping reason scientific, operational, financial, strategic, or mixed?
- What human safety and efficacy evidence actually exists beyond the registry summary?
- Who controls the relevant rights, and are they practically obtainable?
- Is there an indication and endpoint where a smaller experiment could answer the key decision?
- Would the resulting data be usable by the regulator that matters?
Source: ClinicalTrials.gov NCT06039202. Registry information is sponsor/investigator submitted; verify primary evidence before making development decisions.